


**Fondazione
Natalino Corazza
Psoriasis & Co.
October 29, 2016**





**Department of Dermatology
Medical University of Vienna**


UNDERSTANDING PSORIASIS – A PARADIGM FOR MAJOR EVOLUTIONS IN DERMATOLOGY

**Klaus Wolff, MD, FRCP
Professor emeritus
Medical University of Vienna**











Proposed model integrating the genetics and immunology of psoriasis





THE THERAPY OF PSORIASIS

From Empirism to Targeted Treatments


Major Steps

- Topical: anthralin, tar, corticosteroids
- Light: solar, UVB, Goeckerman
- PUVA
- Retinoids
- Immunosuppressive Agents: MTX, Cyclosporin
- Calcineurin inhibitors
- „Biologicals“

PUVA

is based on the interaction of an orally administered photosensitizer (psoralen) and UV-A. Drug and UV-A alone are ineffective







Wolff K, Hönigsmann H, Gschnait F, Konrad K:
Photochemotherapie bei Psoriasis. Klinische Erfahrungen
bei 152 Patienten.
Dtsch Med Wschr 100:2471-2477, 1975


**Wolff K, Fitzpatrick TB, Parrish JA, Gschnait F, Gilchrest B,
Hönigsmann H, Pathak A, Tanenbaum L:**
Photochemotherapy for psoriasis with orally administered
methoxsalen.
Arch Dermatol 112: 943-950, 1976


**Wolff K, Gschnait F, Hönigsmann H, Konrad K, Parrish JA,
Fitzpatrick TB:**
Phototesting and dosimetry for photochemotherapy.
Brit J Dermatol 96:1-10, 1977

**Hönigsmann H, Jaschke E, Gschnait F, Brenner W, Fritsch P,
Wolff K:**
5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
Brit J Dermatol 101:369-378, 1979

Gschnait F, Hönigsmann H, Brenner W, Fritsch P, Wolff K:
Induction of UV light tolerance by PUVA in patients with
polymorphous light eruption.
Brit J Dermatol 99:293-295, 1978








DAY 0


DAY 28

RNA expression changes after pimecrolimus treatment



Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, Kehren J, Chibout SD, Cordier A, Holter W, Richter L, Oberbauer R, Stütz A, Wolff K: Pimecrolimus identifies a common genomic antiinflammatory profile, is clinically highly effective in psoriasis and is well tolerated.

J Invest Dermatol 119:876-887, 2002



Biologics

- **recombinant proteins**
(cytokines, fusion proteins, monoclonal antibodies)
- **produced in bioreactors**
- **selective mode of action**

BIOLOGICS in Psoriasis

TNF α Antagonist	Infliximab, Adalimumab Etanercept
LFA-3/IG	Alefacept
Anti-CD11a	Efalizumab
Anti-IL-12/IL-23p40	Ustekinumab
Anti-IL-17	Secukinumab

„Small Molecules“

Phosphodiesterase	Apremilast Inhibitor
-------------------	-------------------------



before adalimumab



16 weeks after adalimumab

ADVANCES IN PSORIASIS

- improved understanding of molecular mechanisms in psoriasis
- tailored treatments - biologics
- increased awareness of multi co-morbidity in psoriatic patients
- improved understanding of psoriasis as a systemic disease
- improved awareness of psychosocial and socioeconomic burden of psoriasis